Discovery and characterization of a monoclonal antibody targeting conformational epitope of IL-6/IL-6Rα to inhibit IL-6/ IL-6Rα /gp130 hexameric signalling complex formation

PI：Prof. Lin-Hung Wei

Department of Obstetrics & Gynecology, National Taiwan Unuiversity.

Experience:

https://www.ntuh.gov.tw/obgy/Vcard.action?q_type=-1&q_itemCode=650

Market Needs:

IL-6 is a pleiotropic pro-inflammatory cytokine released by T cells, B cells, lymphocytes, monocytes and fibroblasts. IL-6 has been confirmed to activate T cells, promote immunoglobulin secretion, and initiate acute It is related to various physiological responses such as hepatic protein synthesis and stimulation of hematopoietic precursor cell proliferation and differentiation. By neutralizing over-secreted IL-6 molecules, it can modulate downstream signaling and treat related diseases, such as moderate to severe rheumatoid arthritis in adults.

Our Technology:

The present invention is a monoclonal antibody against human interleukin-6 (IL-6) and its receptor.

Strength:

The mechanism of action of the present invention is different from that of existing drugs.

Competing Products:

Tocilizumab, olokizumab。

Intellectual Properties:

(1) This technology has been applied for a US provisional application.
(2) The research team has more than two decades of experience in the study of IL-6 molecules.
(3) This study has been published in the journal mABs.
https://www.tandfonline.com/doi/full/10.1080/19420862.2022.2029675

Contact (do not need to fill out):

Center for Industry-Academia Collaboration, NTU
Tel: 02-3366-9945, E-mail: ordiac@ntu.edu.tw